ライフサイエンスコーパス: poloxamer 188

1 membranes and membranes treated with 1.0 mM poloxamer 188.

2 lipid bilayer of the type that are sealed by poloxamer 188.

3 eversed using the membrane sealant copolymer poloxamer 188.

4 receive an intravenous infusion of purified poloxamer 188, 100 mg/kg for 1 hour followed by 30 mg/kg

5 crisis resolution was increased by purified poloxamer 188 (65/126 [52%] vs 45/123 [37%]; P =.02).

6 33 (41) hours in those treated with purified poloxamer 188, a 9-hour reduction (P =.04).

7 These findings suggest that poloxamer 188 adsorbs into the lipid bilayers, thereby d

8 .0% of Compritol(R) 888 ATO (lipid), 1.5% of poloxamer 188 and 0.1% of the cationic polymer poly(ally

9 and that application of the membrane sealant poloxamer 188 corrects these defects in vitro.

10 Among children and adults with SCD, poloxamer 188 did not significantly shorten time to last

11 s indicated an even more pronounced purified poloxamer 188 effect in children aged 15 years or younge

12 These findings do not support the use of poloxamer 188 for vaso-occlusive episodes.

13 articles (CGT-NP) prepared using gelatin and Poloxamer 188-grafted heparin copolymer demonstrated sig

14 bFGF-loaded NP (bFGF-NP) were prepared with Poloxamer 188-grafted heparin copolymer using water-in-w

15 Adverse events that were more common in the poloxamer 188 group than the placebo group included hype

16 cipants younger than 16 years (88.7 h in the poloxamer 188 group vs 71.9 h in the placebo group; diff

17 t dose of parenteral opioids (81.8 h for the poloxamer 188 group vs 77.8 h for the placebo group; dif

18 g to optimal dosing and long-term effects of poloxamer 188 in humans have been resolved, chemical-bas

19 fety and efficacy of adjunctive therapy with poloxamer 188 in patients receiving thrombolytic therapy

20 xo Wellcome Inc, Research Triangle Park, NC; poloxamer 188) Injection is a nonionic surfactant with h

21 A 1-hour 100-mg/kg loading dose of poloxamer 188 intravenously followed by a 12-hour to 48-

22 RheothRx (poloxamer 188) is a surfactant with hemorheological and

23 Purified poloxamer 188 may increase tissue oxygenation and thereb

24 nic block co-polymeric surface active agent, poloxamer 188, on electroporation of artificial lipid me

25 c administration, and time to treatment with poloxamer 188 or placebo.

26 omized 114 patients to a 48-hour infusion of poloxamer 188 or vehicle placebo beginning immediately a

27 tial, and evaluate the potential benefits of Poloxamer 188 (P-188) in improving mitochondrial quality

28 el muscle cell, were subjected to short-term Poloxamer 188 (P188) and PEO(181) (8,000 g/mol) treatmen

29 repair acutely with the non-ionic surfactant poloxamer 188 (P188) restored cell viability to control

30 The mechanism by which poloxamer 188 (P188) seals a damaged cell membrane is ex

31 Subsequent studies using Poloxamer 188 (P188), a membrane resealing reagent, demo

32 Poloxamer 188 (P188), a non-ionic triblock copolymer, ha

33 the cells were treated with the FDA-approved poloxamer 188 (P188).

34 20 and 80 (PS20 and PS80, respectively) and poloxamer 188 (P188).

35 A previous phase 3 trial of poloxamer 188 reported shortened duration of painful vas

36 Adjunctive therapy with poloxamer 188 resulted in substantial benefit in this ra

37 In vivo administration of poloxamer 188 to dystrophic mice instantly improved vent

38 First, addition of a poloxamer 188 to nanoparticle formulations increased upt

39 charge pulse and voltage clamp experiments, poloxamer 188-treated membranes exhibited a statisticall

40 Also, poloxamer 188-treated membranes were found to have a rel

41 Poloxamer 188-treated patients demonstrated a 38% reduct

42 the symptoms were observed when the purified poloxamer 188-treated patients were compared with the pa

43 Poloxamer 188 treatment also resulted in a reduced incid

44 Although the mechanisms are unproven, poloxamer 188 treatment may accelerate thrombolysis, red

45 Furthermore, addition of poloxamer 188 was found to reduce the membrane capacitan

46 Poloxamer 188 was well tolerated without adverse hemodyn